Table 1.
Baseline findings in relation with nonin-stent restenosis and in-stent restenosis
| Variables | NISR (202) | ISR (104) | P |
|---|---|---|---|
| Age (years) | 62.2±9.2 | 60.8±8.4 | 0.196 |
| Sex, n (%) | |||
| Male | 138 (68.3) | 77 (74.8) | 0.101 |
| Female | 64 (31.7) | 26 (25.2) | |
| Hypertension, n (%) | 131 (70.4) | 55 (52.9) | 0.051 |
| Diabetes mellitus, n (%) | 70 (34.7) | 63 (60.6) | <0.001 |
| Positive smoking habit, n (%) | 33 (16.7) | 13 (13.0) | 0.271 |
| Statin consumption, n (%) | 185 (94.4) | 93 (95.9) | 0.235 |
| Aspirin consumption, n (%) | 187 (95.4) | 94 (95.9) | 0.305 |
| Clopidogrel consumption, n (%) | 171 (87.7) | 88 (90.7) | 0.234 |
| Stent type, n (%) | |||
| Bare | 51 (39.5) | 38 (60.3) | 0.005 |
| Drug eluting | 78 (60.5) | 25 (39.7) | |
| SBP (mean±SD) | 125.4±16.6 | 123.2±12.5 | 0.352 |
| DBP (mean±SD) | 77.4±8.8 | 78±7.9 | 0.377 |
| FBG (mg/l) | 109.9±57.0 | 126.5±66.9 | 0.038 |
| TG (mg/l) | 108 (79-146) | 127 (78.5-192.5) | 0.039 |
| TC (mg/l) | 148.9±39.8 | 153.7±41.2 | 0.347 |
| LDL (mg/l) | 89.3±32.0 | 88.3±30.3 | 0.807 |
| HDL (mg/l) | 35.7±10.7 | 35±8.4 | 0.581 |
| hs-CRP (mg/l) | 2.3 (1.3-4.2) | 3.46 (1.8-7.8) | 0.006 |
| BMI (kg/m2), n (%) | |||
| Normal | 72 (39.3) | 29 (31.5) | 0.333 |
| Overweight | 85 (46.4) | 45 (48.9) | |
| Obese | 26 (14.2) | 18 (19.6) | |
| Restenosis interval (months) | 36.00 (12.00-60.00) | 6.00 (4.00-8.00) | <0.001 |
SBP=Systolic blood pressure; DBP=Diastolic blood pressure; FBG=Fasting blood glucose; TG=Triglyceride; TC=Total cholesterol; HDL=High-density lipoprotein; LDL=Low-density lipoprotein; hs-CRP=High sensitivity C-reactive protein; BMI=Body mass index; NISR=Nonin-stent restenosis; ISR=In-stent restenosis; SD=Standard deviation